99mTc-Sestamibi Thyroid Scintigraphy in Amiodarone-Induced Thyrotoxicosis: Functional Imaging–Histopathologic Correlation. (15th September 2022)

• Record Type: Journal Article
• Authors: Wang, Ray; Better, Nathan; Sivaratnam, Dinesh; Westcott, James; Forehan, Simon; Christie, Michael; Pattison, David A.; Fourlanos, Spiros
• Is Part Of: Clinical nuclear medicine. Volume 47:Number 9(2022)
• Page Start: e582
• Page End: e584
• Publication Date: 2022-09-15
• Subjects: amiodarone -- sestamibi -- thyroid imaging -- thyrotoxicosis -- total thyroidectomy; Nuclear medicine -- Periodicals; Radioisotope scanning -- Periodicals; Nuclear Medicine -- Periodicals; 616.07575
• DOI: 10.1097/RLU.0000000000004332
• Languages: English
• ISSNs: 0363-9762

Abstract

Abstract: 99m Tc-sestamibi thyroid scintigraphy (STS) can aid in differentiating between types 1 and 2 amiodarone-induced thyrotoxicosis (AIT). We present a consecutive case series of 4 men (aged 56–75 years) in whom both 99m Tc-STS and thyroid histology were consistent with a diagnosis of type 2 AIT, representing the first reported histopathologic correlation for this diagnostic test. Median amiodarone treatment duration was 26 months (range, 10–39 months), and amiodarone was discontinued a median of 3 months preoperatively (range, 2–4 months) in all 4 cases. 99m Tc-STS is a promising functional imaging modality, which has the potential to aid clinicians in the diagnostic workup and treatment of AIT.